[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363394-105":59,"doc-detail-363394-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","extracellular-matrix-driven-patient-stratification-and-network-modeling-reveal-distinct-molecular-grades-with-potential-clinical-implications","Extracellular matrix-driven patient stratification and network modeling reveal distinct molecular grades with potential clinical implications","","Extracellular matrix (ECM) composition shapes tumor fate and treatment outcome, but its heterogeneity across tumors makes impact assessment difficult. An ECM-guided patient stratification pipeline integrates multi-omic data in lung cancer to define four ECM-grade groups with distinct clinical traits, mutation profiles, and cellular heterogeneity. Network modeling identifies ECM-induced intracellular signaling enriched for EMT and cancer stemness regulators. Network-based drug proximity analysis predicts ECM-grade dependent olaparib and ECM-insensitive erlotinib, validated experimentally on lung tumor cells under different ECM microenvironments.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/extracellular-matrix-driven-patient-stratification-and-network-modeling-reveal-distinct-molecular-grades-with-potential-clinical-implications/363394/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/extracellular-matrix-driven-patient-stratification-and-network-modeling-reveal-distinct-molecular-grades-with-potential-clinical-implications/363394.png","ImageObject",300,407,{"name":92,"@type":93},"supergirl","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address regarding the extracellular matrix (ECM)?","Question",{"text":112,"@type":113},"The study addresses how ECM compositional heterogeneity across tumors makes it difficult to assess ECM impact on tumor dynamics and clinical outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How are patients stratified in the proposed approach?",{"text":117,"@type":113},"Patients in lung cancer are stratified by an ECM-guided pipeline that integrates multi-omic data, assigns each patient an ECM grade, and groups patients into distinct ECM-grade categories.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic predictions and validations are reported?",{"text":121,"@type":113},"Drug proximity analysis on ECM-grade specific networks predicts olaparib as ECM-grade dependent and erlotinib as ECM-insensitive; these predictions are validated experimentally on lung tumor cells with distinct mutational profiles under different ECM microenvironments.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363394,1790396990,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","npj | systems biology and applications Article  \n\n| Published in partnership with the Systems Biology Institute |  | |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s41540-026-00697-0](https://doi.org/10.1038/s41540-026-00697-0) |  |  |\n| Extracellular matrix-driven patient stratiﬁcation and network modeling reveal distinct molecular grades with potential clinical implications\u003Cbr> Check for updates |  |  |\n| Aslı Dansık1,2,3, Sevgi Sarıca1,4, Ece Öztürk1,5,6  & Nurcan Tuncbag2,5,7  |  |  |\n| The extracellular matrix (ECM) critically shapes tumor fate and treatment outcome, serving as a potent prognostic factor. Yet, its compositional heterogeneity across tumors makes it difﬁcult to assess its impact on tumor dynamics. To address this, we introduce an ECM-guided patient stratiﬁcation pipeline through integration of multi-omic data in lung cancer patients. We obtained four patient groups, representing ECM-grades that showed distinct clinical features, mutation proﬁles, and cellular heterogeneity. Investigation of patient-speciﬁc ECM-induced intracellular signaling via network modeling revealed strong enrichment of pathways and transcriptional regulators related to epithelialmesenchymal transition (EMT) and cancer stemness in higher ECM-grades. Drug proximity analysis on ECM-grade speciﬁc networks predicted olaparib as an ECM-grade dependent therapeutic while erlotinib to be ECM-insensitive which were validated experimentally on lung tumor cells with distinct mutational proﬁles in response to differing ECM microenvironments. Overall, our ECM-mediated stratiﬁcation approach is a robust system for capturing ECM heterogeneity and identifying patient groups that can be selectively targeted by distinct therapeutic strategies. |  |  |\n| The extracellular matrix (ECM) is an essential regulator of tissue architecture and cellular behavior1. It acts as a dynamic reservoir of bioactive molecules, providing both biochemical and mechanical cues that shape cell fate and function2–4. Through continuous bidirectional communication with surrounding cells, the ECM undergoes active remodeling, altering its composition and mechanical properties to form tissue-speciﬁcmicroenvironments5,6. In tumors, profound alterations of ECM critically shape cancer progression and treatment outcomes7 by triggering various processes such as invasion, angiogenesis, epithelial-to-mesenchymal transition (EMT) and metastasis8–14. Among them, reduced proteoglycan expression in the ECM leads to better overall survival in patients with lung cancer15, 16. Elevated expression of cell instructive ECM moieties can induce immune suppression and therapeutic resistance17, 18. The ECM interacts not only with cancer cells but also with stromal populations such as the cancerassociated ﬁbroblasts (CAFs) and immune cells within the tumor microenvironment (TME) which leads to tumor growth and progression19–22. | Thus, it is essential to investigate the cellular heterogeneity ofthe TME and the reciprocal relationship between diverse cellular populations and the altered ECM characteristics23.\u003Cbr>Remodeling the ECM in the TME is highly heterogeneous across patient tumors. Puttock et al. revealed ﬁve different ECM composition groups by performing hierarchical clustering on the proteomic data of ovarian cancer samples24. Similarly, Bergamaschi et al. found four ECM subgroups in breast carcinomas by performing differential expression analysis on a set ofECM genes, further demonstrating the clinical relevance of these groups25. Pankova et al. revealed three subtypes for dedifferentiated liposarcomas (DDLPS) by clustering matrisome/adhesome protein expressions26. Parker et al. showed two matreotypes in the squamous cell carcinoma subtype of non-small cell lung cancer (NSCLC) based on expression levels of the ECM genes, with one matreotype having low expression and the other with higher expression, and further investigated the differences in these matreotypes27. These studies underscored the ","cbCaipwmZ7JGXEBs","https://ap.wps.com/l/cbCaipwmZ7JGXEBs","pdf",3783921,16,"English","# ECM-guided patient stratification pipeline\n## Multi-omics integration and ECM-grade definition\n## Network modeling of ECM-induced signaling\n## Drug proximity analysis and experimental validation","[{\"question\":\"What problem does the study address regarding the extracellular matrix (ECM)?\",\"answer\":\"The study addresses how ECM compositional heterogeneity across tumors makes it difficult to assess ECM impact on tumor dynamics and clinical outcomes.\"},{\"question\":\"How are patients stratified in the proposed approach?\",\"answer\":\"Patients in lung cancer are stratified by an ECM-guided pipeline that integrates multi-omic data, assigns each patient an ECM grade, and groups patients into distinct ECM-grade categories.\"},{\"question\":\"What therapeutic predictions and validations are reported?\",\"answer\":\"Drug proximity analysis on ECM-grade specific networks predicts olaparib as ECM-grade dependent and erlotinib as ECM-insensitive; these predictions are validated experimentally on lung tumor cells with distinct mutational profiles under different ECM microenvironments.\"}]","Extracellular matrix-driven patient stratification and network modeling reveal distinct molecular grades with potential clinical implications | PDF",1790151046,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c5d7b967a1e6308a6057a0d8cc8a8971.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5bb1a3c9dccedd85a4515ef5f50557d5.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b5a2ede70760b4ca5f23a5224e76603.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2e4fac430914cb9046a441aa332fd7a.webp",980,1301]